西部中医药
西部中醫藥
서부중의약
GANSU JOURNAL OF TRADITIONAL CHINESE MEDICINE
2015年
5期
118-120
,共3页
剖宫产术后%再次足月妊娠%阴道分娩
剖宮產術後%再次足月妊娠%陰道分娩
부궁산술후%재차족월임신%음도분면
after cesarean section%the second full-term pregnancy%vaginal delivery
目的:探讨剖宫产术后再次足月妊娠阴道分娩成功率的方法。方法:将剖宫产后再次足月妊娠孕妇(上次剖宫产病因均非产道因素,本次无阻道分娩禁忌症,有阴道分娩愿望)64例随机抽样分为2组,采用不同方法启动产程,研究组应用米索前列醇加中药降子汤,对照组按常规静脉滴注缩宫素,观察比较2组孕妇分娩情况。结果:与对照组比较,研究组在潜伏期、总产程所用时间及阴道分娩成功率方面优于对照组(P<0.05);在产后出血及子宫破裂发生率、新生儿并发症方面与对照组相当(P>0.05)。结论:应用米索前列醇加中药降子汤可提高剖宫产后再次足月妊娠阴道分娩的成功率;缩短潜伏期、总产程;且不增加子宫破裂发生率、新生儿窒息、新生儿病死率。
目的:探討剖宮產術後再次足月妊娠陰道分娩成功率的方法。方法:將剖宮產後再次足月妊娠孕婦(上次剖宮產病因均非產道因素,本次無阻道分娩禁忌癥,有陰道分娩願望)64例隨機抽樣分為2組,採用不同方法啟動產程,研究組應用米索前列醇加中藥降子湯,對照組按常規靜脈滴註縮宮素,觀察比較2組孕婦分娩情況。結果:與對照組比較,研究組在潛伏期、總產程所用時間及陰道分娩成功率方麵優于對照組(P<0.05);在產後齣血及子宮破裂髮生率、新生兒併髮癥方麵與對照組相噹(P>0.05)。結論:應用米索前列醇加中藥降子湯可提高剖宮產後再次足月妊娠陰道分娩的成功率;縮短潛伏期、總產程;且不增加子宮破裂髮生率、新生兒窒息、新生兒病死率。
목적:탐토부궁산술후재차족월임신음도분면성공솔적방법。방법:장부궁산후재차족월임신잉부(상차부궁산병인균비산도인소,본차무조도분면금기증,유음도분면원망)64례수궤추양분위2조,채용불동방법계동산정,연구조응용미색전렬순가중약강자탕,대조조안상규정맥적주축궁소,관찰비교2조잉부분면정황。결과:여대조조비교,연구조재잠복기、총산정소용시간급음도분면성공솔방면우우대조조(P<0.05);재산후출혈급자궁파렬발생솔、신생인병발증방면여대조조상당(P>0.05)。결론:응용미색전렬순가중약강자탕가제고부궁산후재차족월임신음도분면적성공솔;축단잠복기、총산정;차불증가자궁파렬발생솔、신생인질식、신생인병사솔。
Objective:To explore vaginal delivery success rate of the second full-term pregnancy after cesarean section. Methods:Sixty-four pregnant women (the cause of cesarean section is not birth canal last time, there is no contraindication of childbirth this time and the patients expressing their wish of vaginal delivery) were randomly allocated to two groups, and they were administered with different methods to start their labor, the trial group took misoprostol and JiangZi Tang, the control group received intravenous dripping of oxytocin, the delivery conditions of both groups were compared. Results:Compared with the control group, the trial group was superior to the control group in incubation period, the time of total labor, vaginal delivery success rate (P<0.05);equivalent to the control group in postpartum hemorrhage, the incidence of uterine rupture and neonatal complications (P>0.05). Conclusion:Misoprostol and JiangZi Tang could improve vaginal delivery success rate of the second full-term pregnancy after cesarean section; shorten incubation period and total labor, and the therapy won't affect the incidence of uterine rupture, neonatal asphyxia, neonatal morbidity and mortality.